2016 Fiscal Year Final Research Report
Molecular Targeted Therapy Utilizing Galanin receptor type 2 signaling for Head and Neck Cancer
| Project/Area Number |
26462620
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Otorhinolaryngology
|
|---|
| Research Institution | Jichi Medical University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Keywords | 頭頸部癌 / 分子標的治療 / GPCR / アポトーシス |
|---|
| Outline of Final Research Achievements |
To develop of the novel agents targeted for Galanin receptor type 2, the GALR2 was transfected and transduced into several head and neck squamous cell carcinoma (HNSCC) cell lines. The established stably GALR2 expressing HNSCC cells and adeno-associated virus vectors harboring GALR2 gene transduced cells were investigated the killing effect and signaling pathway after various GALR2 agonists. Galanin-like peptide (GALP) was the most powerful stimulator for GALR2 induced killing effect among some GALR2 agonists. All GALR2 agonists induced both cell cycle arrest and apoptosis, and GALP was the strongest apoptosis inducer. GALP and Galanin suppressed both MAP kinase pathway and PI3K/Akt pathway, but PI3K/Akt pathway suppression was observed in lower dose of GALP compared with Galanin. The killing effect was not observed after cetuximab alone, but the additional effects was observed in GALR2 stably expressing HNSCC cells.GALP would be potential agents for HNSCC therapy.
|
| Free Research Field |
頭頸部外科学
|
